Sumit K. Subudhi, MD, PhD, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer.
Sumit K. Subudhi, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer (mHSPC).
The phase 3 ARCHES trial of enzalutamide (Xtandi) was the first trial in mHSPC to demonstrate a survival benefit with a second-generation androgen-receptor antagonist vs placebo, Subudhi explains. These agents were initially utilized in the metastatic castration-resistant prostate cancer (mCRPC) setting. Enzalutamide was first approved in the post-docetaxel (Taxotere) setting when docetaxel was given in the castration-resistant setting. Later, enzalutamide moved into the pre-docetaxel setting for patients with mCRPC, Subudhi says.
Now, enzalutamide is used when a patient is initially diagnosed with metastatic disease, which comprises the hormone-naïve or castration-sensitivesettings based on the survival advantage of the ARCHES trial, Subudhi concludes.